Clinical trials: 2019-nCoV
Coronavirus Disease 2019 (COVID19)
Screening for Patients Admitted to Ain-Shams University Hospitals for SARS-COV-2 (COVID19)
The objective of this study is to screen the patients seeking hospitalization in Ain Shams university hospitals and identify a cost effective tool for continuing screening the patients all through the epidemic period
- Trial name
- NCT04443712
- Where
- Egypt
- Volunteers
- 1,900 people
- Sponsor
- Samia Girgis
2019-nCoV
Clinical Study of Arbidol Hydrochloride Tablets in the Treatment of Pneumonia Caused by Novel Coronavirus
In the absence of 2019-ncov specific therapeutic drugs, arbidol is effective against a variety of coronaviruses in vitro pharmacodynamics.
- Trial name
- NCT04260594
- Testing
- Arbidol, basic treatment
- Where
- China
- Volunteers
- 236 people
- Sponsor
- Jieming QU
Coronavirus Disease 2019 (COVID-19), SARS-CoV-2
COVID-19: Human Epidemiology and Response to SARS-CoV-2
The human disease caused by SARS-CoV-2 is called COVID-19. In most cases, COVID-19 presents as a mild to moderate respiratory illness. But it can also be more severe and even lead to death.
- Trial name
- HEROS (NCT04375761)
- Testing
- Collection of Biological Samples, Symptom and Exposure Surveys
- Where
- 20 sites in United States
- Volunteers
- 5,599 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
COVID-19, COVID-19 Immunisation
Safety and Immunogenicity Study of 2019-nCoV Vaccine (mRNA-1273) for Prophylaxis of SARS-CoV-2 Infection (COVID-19)
This is a phase I, open-label, dose-ranging clinical trial in males and non-pregnant females, starting at 18 years of age, inclusive, who are in good health and meet all eligibility criteria.
- Trial name
- NCT04283461
- Testing
- mRNA-1273
- Where
- 3 sites in United States
- Volunteers
- 120 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
SARS-CoV2 Infection
The Efficacy of Vitamin D Supplementation in Patients With Severe and Extremely Severe COVID-19
Despite the successful treatment of patients with moderate coronavirus disease 2019 (COVID-19), outcomes for patients with severe disease remain unsatisfactory.
- Trial name
- COVID-VIT (NCT05092698)
- Testing
- Vitamin D (cholecalciferol), Herbal oil
- Where
- Russia
- Volunteers
- 110 people
- Sponsor
- Federal Research Clinical Center of Federal Medical & Biological Agency, Russia
Coronavirus Disease 2019
Fostamatinib for Hospitalized Adults With COVID-19
Background: COVID-19 is a new disease caused by SARS-CoV-2 that was identified in 2019. Some people who get sick with COVID-19 become ill requiring hospitalization. There are some medicines that may help with recovery.
- Trial name
- NCT04579393
- Testing
- fostamatinib
- Where
- 2 sites in United States
- Volunteers
- 59 people
- Sponsor
- National Heart, Lung, and Blood Institute (NHLBI)
COVID, Sars-CoV2
Whole Blood Collection From Individuals in the Convalescent Phase of SARS-CoV-2 Infection
The study was not opened.
- Trial name
- NCT04409184
- Volunteers
- healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin
Coronavirus Disease 2019 (COVID-19)
Evaluation of Silver Nanoparticles for the Prevention of COVID-19
In this research, silver nanoparticles (AgNPs) were tested in vitro and shown to have an inhibitory effect on SARS-CoV-2 infection in cultured cells.
- Trial name
- COVID-19 (NCT04894409)
- Testing
- Mouthwash and nose rinse with the AgNPs solution, Mouthwashes and nose rinse in a conventional way
- Where
- Mexico
- Volunteers
- 231 people, healthy volunteers welcome
- Sponsor
- Cluster de Bioeconomia de Baja California, A.C
2019 nCoV, PD-1
Immunoregulatory Therapy for 2019-nCoV
Sepsis, including viral infections, are major causes of death worldwide. Studies show that in 2017, the number of sepsis patients worldwide reached as high as 48.9 million, of which 11 million patients died.
- Trial name
- NCT04268537
- Testing
- PD-1 blocking antibody+standard treatment, Thymosin+standard treatment, standard treatment
- Volunteers
- 120 people
- Sponsor
- Southeast University, China
Coronavirus Disease 2019 (COVID-19) Pneumonia
Saliva PCR in Pregnant Women with COVID-19
Abstract: Objectives We aim to study the relative viral load using saliva polymerase chain reaction among pregnant women treated with Paxlovid.
- Trial name
- NCT06735300
- Testing
- Nirmatrelvir/Ritonavir (Paxlovid)
- Where
- Taiwan
- Volunteers
- 37 people
- Sponsor
- National Cheng-Kung University Hospital
COVID
Validation of an Immunochromatographic Assay for IgG/IgM Antibodies to 2019- nCoV
In COVID-19 pandemic, it is of critical importance to identify a rapid and simple diagnostic method to be used in clinical settings to timely inform and refine strategies that can prevent, control, and stop the spread of…
- Trial name
- I-GLOBAL (NCT04434417)
- Testing
- 2019-nCoV IgG/IgM Rapid Test Cassette
- Where
- 5 sites in Italy
- Volunteers
- 1,000 people
- Sponsor
- European Institute of Oncology
Cardiovascular Death; Major Adverse Cardiovascular Events
2019-nCoV Outbreak and Cardiovascular Diseases
Cardiovascular events occurring after 2019-nCoV outbreak in Jinan were prospectively assessed by emergency physicians. We compared those events with events that occurred during the past 3 months and the same months of the last…
- Trial name
- NCT04255940
- Where
- 12 sites in China
- Volunteers
- 12,000 people
- Sponsor
- Qilu Hospital of Shandong University
COVID-19
Randomized Multicenter Study on the Efficacy and Safety of Favipiravir for Parenteral Administration Compared to Standard of Care in Hospitalized Patients With COVID-19
This is open-labe randomized multicenter comparative Phase III study conducted in 7 medical facilities. The objective of the study is to assess the efficacy and safety of Favipiravir for parenteral administration compared with…
- Trial name
- NCT05185284
- Testing
- Favipiravir, Remdesivir
- Where
- 6 sites in Russia
- Volunteers
- 217 people
- Sponsor
- Promomed, LLC
Covid19 Virus Infection
Medical Herbs Inhibit Inflammation Directing T Cells to Kill the COVID-19 Virus (COVID)
The human immune system is designed to protect individuals from external sources of infection and internal cell mutation. It works effectively and efficiently until inflammation disturbs its functioning.
- Trial name
- COVID (NCT04790240)
- Testing
- Inflammation (I), Inflammation (II), Inflammation (III)
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- All Natural Medicine Clinic, LLC
2019-nCoV
A Prospective/Retrospective,Randomized Controlled Clinical Study of Antiviral Therapy in the 2019-nCoV Pneumonia
At present, there is no specific and effective antiviral therapy.In this study, an open, prospective/retrospective, randomized controlled cohort study was designed to compare the efficacy of three antiviral drugs in the treatment…
- Trial name
- NCT04255017
- Testing
- Abidol hydrochloride, Oseltamivir, Lopinavir/ritonavir
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Tongji Hospital
COVID-19
Study to Evaluate the Effects of RO7496998 (AT-527) in Non-Hospitalized Adult and Adolescent Participants With Mild or Moderate COVID-19
This study will evaluate the efficacy, safety, antiviral activity, and pharmacokinetics of study drug RO7496998 (AT-527) compared to placebo in non-hospitalized adult and adolescent participants with mild to moderate coronavirus…
- Trial name
- MORNINGSKY (NCT04889040)
- Testing
- RO7496998
- Where
- 50 sites in Argentina, Belgium and 10 more
- Volunteers
- 216 people
- Sponsor
- Hoffmann-La Roche
Covid19
Early Detection of COVID-19 Using Breath Analysis - Feasibility Study
Early Detection of COVID-19 Using Breath Analysis -Feasibility Study.
- Trial name
- COVID-19 (NCT04602871)
- Testing
- Breath Biopsy
- Where
- 2 sites in Israel
- Volunteers
- 54 people, healthy volunteers welcome
- Sponsor
- Scentech Medical Technologies Ltd
COVID-19
Safety and Immunogenicity Study in Adults of AZD1222 and rAd26-S Administered as Heterologous Prime Boost Regimen for the Prevention of Coronavirus Disease 2019 (COVID-19)
This is a Phase I/II, parallel group, single blinded (participant blinded), randomised study assessing the immunogenicity and safety of AZD1222 and rAd26-S administered as heterologous prime-boost in alternating order in 2 study…
- Trial name
- NCT04760730
- Testing
- AZD1222, rAd26-S
- Where
- United Arab Emirates
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- R-Pharm
Corona Virus Infection
Norwegian Coronavirus Disease 2019 Study
In the current proposal, the investigators aim to investigate the virological and clinical effects of chloroquine treatment in patients with established COVID-19 in need of hospital admission.
- Trial name
- NO COVID-19 (NCT04316377)
- Testing
- Hydroxychloroquine Sulfate
- Where
- Norway
- Volunteers
- 53 people
- Sponsor
- University Hospital, Akershus
Covid19
Point of Care Evaluation of Novir 2019-nCoV Immunoglobulin G/ Immunoglobulin M (IgG/IgM) Antibody Test (Collodial Gold)
This clinical study is designed to test the efficacy of the Novir 2019-nCoV Immunoglobulin M/Immunoglobulin G Antibody Test in a point-of-care setting to support the increasing need for rapid screening in the detection of…
- Trial name
- NOVIR POC (NCT04902911)
- Testing
- COVID-19 SARS-CoV IgG/IgM antibody rapid test
- Where
- United States
- Volunteers
- 91 people, healthy volunteers welcome
- Sponsor
- Medical College of Wisconsin